

Exhibit 3. Professor James W Ironside

Published references cited in Witness Statement text (numbered in order of citation)

1. Ludlam CA. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. **Lancet** 1997;350:1704.
2. Ghani A, Ferguson NM, Donnelly CA et al. Estimation of the number of people incubating vCJD in 1998. **Lancet** 1998;352:1353-1354.
3. Garske T, Ghani AC. Uncertainty in the tail of the vCJD epidemic in the UK. **PLoS One** 2010;5:e15626.
4. Gill ON, Spence Y, Richard-Loendt et al. Prevalence of abnormal PrP in human appendices in UK. **Acta Neuropathol** 2020;139:965-976.
5. Mok T, Jaunmuktane Z, Joiner S et al. Variant Creutzfeldt–Jakob disease in a patient with heterozygosity at PRNP codon 129. **New Engl J Med** 2017;376:292-294.
6. Urwin P, Thanigaikumar K, Ironside JW et al. 2 sCJD cases in UK fractionated plasma product recipients. **Emerg Infect Dis** 2017;23: 893-897.
7. Ironside JW, McCardle L, Horsburgh A et al. Pathological diagnosis of vCJD. **APMIS** 2002;110:78-82.
8. Concha-Marambio L, Priytkow S, Moda F et al. Detection of prions in blood from patients with vCJD. **Sci Transl Med** 2016;8: 70ra183. doi:10.1126/scitranslmed.aaf6188.
9. Bougard D, Brandel J-P, Belondrade M et al. Detection of prions in the plasma of presymptomatic and symptomatic patients with vCJD. **Sci Transl Med** 2016;8: 370ra182. doi: 10.1126/scitranslmed.aag1257.
10. Bruce ME, Will RG, Ironside JW et al. Transmissions to mice indicate that vCJD is caused by the BSE agent. **Nature** 1997;389:498-501.
11. Beekes M, McBride PA. The spread of prions through the body in naturally acquired transmissible spongiform encephalopathies. **FEBS Journal** 2007;274:588-605.
12. Salamat MKF, Alejo Blanco AR, McCutcheon S et al. Preclinical transmission of prions by blood transfusion is influenced by donor genotype and route of infection. **PLoS Pathog** 2021; doi.org/10.1371/journal.ppat.1009267.
13. Peden AH, Head MW, Ritchie DL et al. Preclinical vCJD following blood transfusion in a codon 129 recipient. **Lancet** 2004;364:527-529.

14. Bishop MT, Diack AB, Ritchie DL et al. Prion Infectivity in the spleen of a PRNP heterozygous patient with subclinical vCJD. **Brain** 2013;136;1139-1145.
15. Millar CM, Connor C, Dolan G et al. Risk reduction strategies for vCJD transmission by UK plasma products and their impact on patients with inherited bleeding disorders. **Haemophilia** 2010;16:305-315.
16. Huang Y, Gregori L, Anderson SA et al. Development of dose-response models of Creutzfeldt-Jakob disease infection in nonhuman primates for assessing the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease. **J Virol** 2014;88:13732-13736.
17. Boelle P-Y, Cesbron J-Y, Valleron A-J. Epidemiological evidence of higher susceptibility to vCJD in the young. **BMC Infect Dis** 2014;4:26 doi:10.1186/1471-2334-4-26.
18. Ghani AC, Donnelly CA, Ferguson NM et al. Updated projections of future vCJD deaths in the UK. **BMC Infect Dis** 2003;3:4 1471/23343/4.
19. Uttley L, Carroll C, Wong R et al. Creutzfeldt-Jakob disease - a systematic review of global incidence, prevalence, infectivity, and incubation. **Lancet Infect Dis** 2020;20:e2-10.
20. Beringue V, Vilotte J-L, Laude H. Prion agent diversity and species barrier. **Vet Res** 2008;39:47 doi: 10.1051/vetres:2008024.
21. Diack AB, Boyle A, Plinston C et al. Variant Creutzfeldt-Jakob disease strain is identical in individuals of two PRNP codon 129 genotypes. **Brain** 2019;142:1416-1428.
22. Will RG, Ironside JW. Sporadic and Infectious Human Prion Diseases. **Cold Spring Harb Perspect Med** 2017;7:a024364.
23. Murray K, Peters J, Stellitano L et al. Is there evidence of vertical transmission of vCJD? **J Neurol Neurosurg Psych** 2011;82:7290731.
24. Ironside JW, Sutherland K, Bell JE et al. A new variant of Creutzfeldt-Jakob disease: Neuropathological and clinical features. **Cold Spring Harb Symp Quant Biol** 1996;61:523-530.
25. Chazot G, Broussolle E, Lapras CI et al. New variant of Creutzfeldt-Jakob disease in a 26-year-old French man. **Lancet** 1996;347:1181.
26. Lasmezias CI, Deslys J-P, Demainay R et al. BSE transmission to macaques. **Nature** 1996;381:743-744.
27. Collinge J, Sidle KC, Meads J et al. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. **Nature** 1996;383:685-690.

28. Diack AB, McCutcheon S, Boyle A et al. Variant CJD. 18 years of research and surveillance. **Prion** 2014;8:286-295.
29. Ward JJT, Everington D, Cousens S et al. Risk Factors for vCJD. A case-control study. **Ann Neurol** 2006;59:111-120.
30. Bell JE, Ironside JW. Principles and practice of high risk brain banking. **Neuropathol Appl Neurobiol** 1997;23:281-288.
31. Hill AF, Butterworth AJ, Joiner S. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. **Lancet** 1999;353:183-189.
32. Hilton D, Father SE, Edwards P. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. **Lancet** 1998;352:703-704.
33. Schreuder BEC, van Keulen LJM, Vromans MEW et al. Preclinical test for prion diseases. **Nature** 1996;381:563.
34. Ironside JW, Hilton DA, Ghani AC et al. Retrospective study of prion-protein accumulation in tonsil and appendix tissues. **Lancet** 2000;355:1693-1694.
35. Hilton DA, Sutak J, Smith MEF et al. Specificity of lymphoreticular accumulation of prion protein for variant Creutzfeldt–Jakob disease. **J Clin Pathol** 2004;57:300-302.
36. Hilton DA, Ghani AC, Conyers L et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. **J Pathol** 2004;203:733-739.
37. Gill ON, Spencer Y, Richard-Loendt et al. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. **Brit Med J** 2013;347:f5675 doi: 10.1136/bmj.f5675
38. Bishop MT, Hart P, Aitchison L. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. **Lancet Neurol** 2006;5: 393-398.
39. Powell-Jackson J, Weller RO, Kennedy P et al. Creutzfeldt-Jakob disease after administration of human growth hormone. **Lancet** 1985;2:244-246.
40. Seed CR, Hewitt PE, Dodd RY et al. CJD and blood transfusion Safety. **Vox Sang** 2018;113:220-231.
41. Brown P. Blood infectivity, processing and screening tests in transmissible spongiform encephalopathy. **Vox Sang** 2005;89:63-70.
42. Bruce M, McConnell I, Will RG et al. Detection of variant Creutzfeldt- Jakob disease infectivity in extraneural tissues. **Lancet** 2001;358: 208-209.
43. Grist PM. Transmissible spongiform encephalopathy risk assessment. The UK experience. **Risk Analysis** 2015;25:519-532.

44. CJD Incidents Panel. Management of possible exposure to CJD through medical procedures. A consultation paper. **Department of Health**: 2001.
45. Hall V, Brookes D, Nacul L et al. Managing the risk of iatrogenic transmission of Creutzfeldt-Jakob disease in the UK. **J Hosp Infect** 2014;88:22-27.
46. Millar CM, Markis M. Dealing with the uncertain risk of vCJD transmission by coagulation replacement products. **Brit J Haematol** 2012; 58:442-452.
47. Heath CA, Cooper AA, Murray K et al. Validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. **Ann Neurol** 2010;67:761-770.
48. Edgeworth JA, Farmer M, Sicilia A et al. Detection of prion infection in variant Creutzfeldt-Jakob disease. A blood-based assay. **Lancet** 2011;377:487-493.
49. Jackson GS, Burk-Rafel J, Edgeworth JA et al. Population Screening for Variant Creutzfeldt-Jakob Disease Using a Novel Blood Test. Diagnostic accuracy and feasibility study. **JAMA Neurol** 2014;71:421-428.
50. Bennett P. Blood Test for Variant Creutzfeldt-Jakob Disease. Letter and Reply. **JAMA Neurol** 2014;71:1054-1055.
51. Helbert MR, Bangs C, Bishop M et al. No evidence of vCJD infection in immunodeficiency patients treated with UK -sourced immunoglobulin. **Vox Sang** 2016;110:282-284.
52. Urwin PJM, Mackenzie JM, Llewelyn CA et al. Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK Transfusion Medicine Epidemiology Review Study. **Vox Sang** 2016;110:310-316.